- Heike Brötz-Oesterhelt, Chair of Dept. “Microbial Bioactive Compounds”, Interfaculty Institute of Microbiology and Infection Medicine, Univ. Tuebingen (Germany)
- Scott J. Hecker, Senior Vice President, Chemistry and Chemical Development, Qpex Biopharma (USA)
- Kim Lewis, Northeastern University Distinguished Professor, Director, Antimicrobial Discovery Center (USA)
In this webinar, the speakers discussed the breadth of new approaches to antibiotic discovery with a focus on resolving bottlenecks.
Presentation 1: Natural products in antibacterial drug discovery (Heike Brötz-Oesterhelt)
- This presentation focused on examples of antibacterial agents with complex modes of action, methodology for antibacterial mode of action elucidation, and characteristics of natural products as the starting point for antibacterial drug discovery.
Presentation 2: Discovery of Xeruborbactam (QPX7728), an Ultra-broad-spectrum Boronic Acid Inhibitor of Serine and Metallo Beta-lactamases (Scott J. Hecker)
- This presentation described a discovery program seeking a next-generation boronic acid beta-lactamase inhibitor and culminating with xeruborbactam (QPX7728), now in clinical development.
This live webinar including an interactive Q&A session was broadcast on 11 October 2022.
If you have questions or comments, please let us know: email@example.com.